FDA Approved Use Prevents Hatch-Waxman Patent Infringement Claim: Federal Circuit | Practical Law
In the consolidated appeals of Bayer Schering Pharma v. Lupin Ltd. and Bayer Schering Pharma v. Sandoz, Inc., the US Court of Appeals for the Federal Circuit affirmed a district court's decisions that the defendants' ANDAs for a generic drug did not infringe a method-of-use patent for Bayer's Yasmin drug. Specifically, a divided panel determined that Bayer failed to state a claim for patent infringement because the defendants sought approval to market the generic form of the Yasmin drug for a use approved by the FDA but not covered by Bayer's patent.